Endothelial dysfunction in diabetes mellitus: new insights
M Dubsky, J Veleba, D Sojakova… - International Journal of …, 2023 - mdpi.com
Endothelial dysfunction (ED) is an important marker of future atherosclerosis and
cardiovascular disease, especially in people with diabetes. This article summarizes the …
cardiovascular disease, especially in people with diabetes. This article summarizes the …
[HTML][HTML] The role of adherence in patients with chronic diseases
M Burnier - European Journal of Internal Medicine, 2023 - Elsevier
In the long-term management of chronic diseases, adherence and persistence to prescribed
medications are continuous challenges in order to obtain all the potential benefits of drug …
medications are continuous challenges in order to obtain all the potential benefits of drug …
FLOW trial stopped early due to evidence of renal protection with semaglutide
On 10 October 2023, Novo Nordisk 1 announced the decision to stop the kidney outcome
trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in …
trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in …
Advancements in Drug Repurposing: Examples in Psychiatric Medications
R Okuyama - International Journal of Molecular Sciences, 2023 - mdpi.com
Because there are a limited number of animal models for psychiatric diseases that can be
extrapolated to humans, drug repurposing has been actively pursued. This study was aimed …
extrapolated to humans, drug repurposing has been actively pursued. This study was aimed …
Current RNA strategies in treating cardiovascular diseases
Cardiovascular disease (CVD) continues to impose a significant global health burden,
necessitating the exploration of innovative treatment strategies. Ribonucleic acid (RNA) …
necessitating the exploration of innovative treatment strategies. Ribonucleic acid (RNA) …
Factor XIa inhibitors: collecting the clinical evidence
BS Lewis, K Hasegawa - European Heart Journal …, 2024 - academic.oup.com
The phase 2 clinical trial AZALEA-TIMI 71, examining the novel factor XI inhibitor
abelacimab in patients with atrial fibrillation, was recently stopped due to 'an overwhelming …
abelacimab in patients with atrial fibrillation, was recently stopped due to 'an overwhelming …
Synthesis and Application of Task-Specific Bimetal–Organic Frameworks in the Synthesis of Biological Active Spiro-Oxindoles
The use of click chemistry as a smart and suitable method for the development of new
heterogeneous catalysts is based on metal–organic frameworks as well as the production of …
heterogeneous catalysts is based on metal–organic frameworks as well as the production of …
Early initiation of SGLT2 inhibitors in Acute Heart failure: a focus on Diuresis and Renal Protection
A Hammer, A Niessner, P Sulzgruber - Cardiovascular Drugs and Therapy, 2023 - Springer
Purpose Acute heart failure (AHF) represents a critical and life-threatening condition
characterized by the sudden onset or exacerbation of symptoms, such as dyspnea and fluid …
characterized by the sudden onset or exacerbation of symptoms, such as dyspnea and fluid …
What's new in pharmacotherapy at ESC Congress 2023?
Heart failure (HF) was the focus of the congress, accounting for nearly a third of the 30 Hot
Line trials. In the STEP-HFpEF trial, 1 which included patients with HF with preserved …
Line trials. In the STEP-HFpEF trial, 1 which included patients with HF with preserved …
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2023
Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their
pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more …
pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more …